In this study, we investigate the potential of repurposing furmonertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as a candidate for reversing MDR mediated by ABCB1 and ABCG2 in multidrug-resistant cancer cells. The gene discussed is EGFR; the disease is cancer.